Pharma / Benefit Plan Settlements


There are often a number of active antitrust settlements and lawsuits that fall into the category of “pharmaceutical settlements.” Under these settlements, it is generally alleged that businesses with self-insured health plans overpaid for drugs purchased on behalf of their employees due to artificially inflated and/or stabilized prices. The prices were allegedly manipulated as a result of anti-competitive practices undertaken by the drug manufacturers.

Available Settlements

Eligible Pharma Product                    Date Range                    Settlement Fund               Filing Deadline       
Thalomid and Revlimid (cancer)           Prior to August 2019       $55 million                         December 30, 2019

Provigil (sleep disorder / narcolepsy)   June 2006 - Aug. 2019    $65 million                         January 15, 2020

Eligible Locations

The settlement covering Thalomid and Revlimid purchases includes organizations in the following locations:

  • California, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee

The settlement covering Provigil purchases includes organizations in the following locations:

  • Alabama, Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Mexico, New York, North Carolina, North Dakota, South Dakota, Tennessee, Utah, Vermont, West Virginia and Wisconsin

Next Steps for MCAG Clients

Data is often required to complete your claim for settlements in this category. MCAG can quickly review the process with you so we can easily obtain necessary information from your Pharmacy Benefit Manager (i.e. CVS Caremark, Express Scripts, OptumRX) to pursue current and future pharmaceutical settlements. Should you wish to proceed, please contact an Account Manager at 800.355.0466 or send an email to settlements@mcaginc.com.